Historical performance in the Healthcare category.
Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Abbott Laboratories | Exact Sciences | Acquisition | $21.3B | Abbott Laboratories acquires Exact Sciences in $21,267.5M deal |
| Investor Group | Hologic | Acquisition | $18.4B | Investor Group acquires Hologic in $18,446.7M deal |
| Boston Scientific | Penumbra | Acquisition | $14.2B | Boston Scientific to acquire Penumbra in $14,235.4M deal |
| Sun Pharmaceutical | Organon & Co. | Acquisition | $11.8B | Sun Pharma buys Organon for $11.75 billion |
| Sun Pharmaceutical Industies | Organon & Co | Acquisition | $11.7B | Sun Pharmaceutical Industies to acquire Organon & Co in $11,698.4M deal |
| Danaher | Masimo | Acquisition | $10B | Danaher to acquire Masimo in $10,026.2M deal |
| Gilead Sciences | Arcellx | Acquisition | $7.6B | Gilead Sciences acquires Arcellx in $7,589.0M deal |
| Asahi Kasei | Aicuris Anti-infective Cures AG | Acquisition | $919M | Asahi Kasei to acquire Aicuris Anti-infective Cures AG in $919.0M cash deal |
| Kimball Electronics, Inc. | Helvoet Polymer Technologies B.V. | Acquisition | $103M | Kimball Electronics Buys Helvoet to Deepen Medical Push |
| Blackstone and TPG | Hologic, Inc. | Acquisition | Undisclosed | Blackstone and TPG acquires Hologic, Inc. in cash and cvr deal |
Page 1 of latest articles and deal coverage.
The $103 million deal gives Kimball a European medical manufacturing base, India exposure, and a faster route into higher-margin device programs.
The deal extends Vizient’s push beyond traditional supply chain contracting into a fast-growing cost category where hospitals have struggled to control vendor sprawl and pricing.
The milestone underscores how private equity firms are industrializing acquisition programs to manufacture growth in a slower volume market.
The all-cash deal gives Sun Pharma scale in women’s health, biosimilars and branded medicines while pushing the Indian drugmaker deeper into global markets and heavier leverage.